Considering the high expression of SOCS1 in mregDCs, genetically modified DCs with SOCS1 silencing were evaluated (NCT01956630) and were found to elicit powerful immune effects and increase the survival of patients with acute myeloid leukaemia.93 This evidence concerns the gene SOCS1 and acute myeloid leukemia.